Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and scientists Richard Mead and Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN).  The company has exclusive rights to develop intellectual property related to a novel chemical series identified at Sheffield. The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.